Medco Research/Repligen hope to be profitable in 1996 under proposed $51.5 mil. non-cash merger.
Executive Summary
MEDCO RESEARCH/REPLIGEN MERGER WOULD LEAD TO PROFITABILITY IN 1996, the companies forecast following a $51.5 mil. proposed merger announced May 23. The road to profitability would be based, in part, upon royalty revenues from Medco Research's two approved products, Adenocard and Adenoscan, and royalties from Repligen's Recombinant Protein A, which is sold to diagnostic kit manufacturers.